TP53 and neoplasm: The distribution of molecular tumour characteristics (KRAS, BRAF, TP53, STK11 and KEAP1 mutations) in the study cohort correlated with the known frequency of mutations, with actionable EGFR and ALK alterations being under‐represented.18, 19